Page last updated: 2024-08-22

lutetium and psma-617

lutetium has been researched along with psma-617 in 59 studies

Research

Studies (59)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	16 (27.12)	24.3611
2020's	43 (72.88)	2.80

Authors

Authors	Studies
Afshar-Oromieh, A; Bauder-Wüst, U; Benešová, M; Eder, M; Haberkorn, U; Kopka, K; Kratochwil, C; Mier, W; Schäfer, M	1
Ahmadzadehfar, H; Essler, M; Knüpfer, E; Schlenkhoff, CD	1
Banerjee, S; Das, T; Guleria, M; Kale, C; Lele, VR; Parab, A; Sarma, HD; Shah, H	1
Chakraborty, S; Chakravarty, R; Dash, A; Sen, IB; Shetty, P; Vimalnath, KV	1
Eiber, M; Heck, MM; Knorr, K; Kratochwil, C; Retz, M; Tauber, R	1
Ahmadzadehfar, H; Becker, A; Eppard, E; Essler, M; Feldmann, G; Fisang, C; Kürpig, S; Yordanova, A	1
Ahmadzadehfar, H; Eppard, E; Essler, M; Fimmers, R; Hauser, S; Kürpig, S; Schlenkhoff, C; Wegen, S; Wei, X; Yordanova, A	1
Akhurst, T; Eu, P; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Jackson, P; Kong, G; Murphy, DG; Ravi Kumar, A; Sandhu, S; Scalzo, M; Thang, SP; Violet, J; Williams, SG	1
Chen, X; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Szajek, LP; Tian, R; Wang, Z	1
Blanksby, A; Crumbaker, M; Emmett, L; Epstein, R; Eu, P; Gedye, C; Guminski, A; Ho, B; Horvath, L; Joshua, AM; Mahon, K; Ratnayake, L; Stricker, P; Willowson, K; Yin, C	1
Belli, ML; Celli, M; Cittanti, C; Di Iorio, V; Ferrari, M; Mezzenga, E; Monti, M; Nicolini, S; Oboldi, D; Paganelli, G; Sarnelli, A; Severi, S; Tardelli, E; Uccelli, L	1
Chen, X; Fan, X; Huo, L; Jacobson, O; Li, F; Lin, Y; Liu, Q; Niu, G; Wang, H; Wang, J; Zang, J; Zhu, Z	1
Burger, IA; Deberle, LM; Eberli, D; Hermanns, T; Kranzbühler, B; Müller, C; Salemi, S; Sulser, T; Umbricht, CA	1
Bakshi, G; Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K; Suman, S; Talole, S	1
Taneja, SS	1
Akhurst, T; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Kong, G; Murphy, DG; Ravi Kumar, AS; Sandhu, S; Thang, SP; Violet, J; Williams, S	1
Belli, ML; Canali, E; Caroli, P; Celli, M; Cremonesi, M; Di Iorio, V; Ferrari, M; Grassi, I; Matteucci, F; Mezzenga, E; Nicolini, S; Paganelli, G; Sansovini, M; Sarnelli, A; Severi, S; Tardelli, E	1
Armstrong, AJ; George, DJ; Harrison, MR; Hoimes, CJ; Kao, C; Karachaliou, GS; Powers, E; Zhang, T	1
Grubmüller, B; Hacker, M; Hartenbach, M; Haug, AR; Kramer, G; Kretschmer-Chott, E; Mitterhauser, M; Pichler, V; Rasul, S; Shariat, S; Vraka, C; Wadsak, W; Wollenweber, T	1
Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA	1
Tagawa, ST	1
Bartholomä, MD; Ezziddin, S; Hierlmeier, I; Holland, JP; Martin, S; Maus, S; Rosar, F; Ruf, J; Tönnesmann, R	1
Armour, A; Beer, TM; Chi, KN; de Bono, J; DeSilvio, M; El-Haddad, G; Fizazi, K; Gericke, G; Herrmann, K; Kpamegan, E; Krause, BJ; Messmann, RA; Morris, MJ; Nordquist, LT; Park, CH; Pérez-Contreras, WJ; Rahbar, K; Sartor, O; Tagawa, ST; Vaishampayan, N	1
de Bakker, M; de Lange, F; Eek, A; Gotthardt, M; Jentzen, W; Konijnenberg, MW; Mehra, N; Muselaers, CHJ; Nagarajah, J; Peters, SMB; Privé, BM; Witjes, JA	1
Hadaschik, B; Herrmann, K	1
Attard, G; Calistri, D; Casadei, C; Celli, M; Conteduca, V; De Giorgi, U; Di Iorio, V; Foca, F; Gurioli, G; Matteucci, F; Monti, M; Nicolini, S; Paganelli, G; Sansovini, M; Severi, S; von Eyben, FE	1
Bartholomä, M; Ezziddin, S; Ghazal, Z; Khreish, F; Linxweiler, J; Marlowe, RJ; Maus, S; Rosar, F; Sabet, A	1
Boros, E; Cingoranelli, SJ; Lapi, SE; Loveless, CS; Schlyer, D; Vaughn, BA	1
Frydenberg, M; Grimes, D; McBean, R; Vasey, P; Wong, D; Yaxley, JW; Yaxley, WJ	1
Drzezga, A; Fischer, T; Hammes, J; Heidenreich, A; Pfister, D; Schmidt, M; Schneider, CA; Täger, P	1
Balieiro, LM; Benedetto, R; Bortoleti de Araújo, E; Brandão Freire, MR; de Jesus Silva, J; de Queiroz Souza Passos, P; Ferreira Dos Santos, CS; Marumo, MH; Pereira Dias, LA; Teixeira, LFS; Vieira, DP; Vivaldini, BF; Wieczorek Villas Boas, CA	1
Hindié, E	1
Kashihara, K; Kashihara, T	1
Berruti, A; Dalla Volta, A; Grisanti, S	1
Kraus, BJ; Morris, MJ; Sartor, O	1
Chandran, E; Figg, WD; Madan, R	1
Byrd, A; Curtis, J; Hicklin, D; Mascari, R; Nichols, C; Orofino, C; Sen, S; Vezzeti, A	1
Gill, HJS; Maheshwari, P; Satapathy, S; Sharma, A; Sood, A	1
Bruchertseifer, F; Hlongwa, KN; Knoesen, O; Lawal, IO; Mahapane, J; Maserumule, LC; Mdlophane, A; Mokoala, KMG; Morgenstern, A; Ndlovu, H; Popoola, GO; Reed, JD; Sathekge, MM; Vorster, M	1
Herrmann, K; Sartor, O	1
Caliebe, A; Jüptner, M; Lützen, U; Marx, M; Osmonov, D; Wrenger, R; Zhao, Y; Zuhayra, M	1
Olivier, T; Powell, K; Prasad, V	1
Garje, R; Parikh, RA; Rumble, RB	1
Garje, R; Hope, TA; Parikh, RA; Rumble, RB	1
Choudhury, AD; Jacene, H; Kelly, E; Kilbridge, KL; Morgans, AK; Pomerantz, M; Ravi, P; Ritzer, J; Robertson, M; Shah, H; Sunkara, R; Taplin, ME; Wei, XX; Whelpley, B; Wolanski, A	1
Baumgarten, J; Chun, FKH; Groener, D; Grünwald, F; Happel, C; Kirkgöze, B; Klimek, K; Mader, N; Nguyen Ngoc, C; Sabet, A; Tselis, N	1
Aggarwal, P; Kaur, K; Mittal, BR; Nagi, S; Periasamy, K; Sood, A	1
Burgard, C; Ezziddin, S; Khreish, F; Maus, S; Rosar, F; Schaefer-Schuler, A	1
Bauder-Wüst, U; Benešová-Schäfer, M; Breyl, H; Poethko, T; Remde, Y; Roscher, M; Schäfer, M; Tömböly, C; Winter, R	1
Antonarakis, ES; Bodei, L; Calais, J; Hope, TA; Iravani, A; Jacene, H; Koo, PJ; Morgans, AK; Morris, MJ; Osborne, JR; Sartor, O; Tagawa, ST; Taplin, ME	1
Ardolino, LC; Armstrong, AJ; Dear, R; Gillessen, S; Joshua, AM	1
de Bakker, M; Dominicus, N; Janssen, M; Konijnenberg, MW; Meeuwis, A; Nagarajah, J; Peters, SMB	1
Bal, C; Ballal, S; Damle, NA; Raju, S; Sahoo, RK; Satapathy, S; Tripathi, M; Yadav, MP	1
Aggarwal, P; Kumar, S; Mahdi, RA; Mittal, BR; Paul, D; Sood, A	1
Das, CK; Goyal, S; Mavuduru, RS; Mittal, BR; Satapathy, S; Shukla, J; Singh, SK; Sood, A	1
Floyd, R; Gardner, L; Spitz, A; Sutton, J	1
Chen, Y; Su, D; Yang, H; Zhang, Y	1

Reviews

4 review(s) available for lutetium and psma-617

Article	Year
[PSMA-targeted radioligand therapy in prostate cancer]. Der Urologe. Ausg. A, 2017, Volume: 56, Issue:1 Topics: Antigens, Surface; Dipeptides; Evidence-Based Medicine; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Isotope Labeling; Lutetium; Male; Molecular Targeted Therapy; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Treatment Outcome	2017
Novel therapies are changing treatment paradigms in metastatic prostate cancer. Journal of hematology & oncology, 2020, 10-28, Volume: 13, Issue:1 Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Clinical Trials as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes	2020
Hematologic toxicity profile and efficacy of [ European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:10 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney Diseases; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Thrombocytopenia; Treatment Outcome	2022
Practical Guidance on [177Lu]Lu-PSMA-617 Treatment, Including Radiation Safety, Adverse Event Monitoring, and Patient Counseling. Clinical journal of oncology nursing, 2023, 09-15, Volume: 27, Issue:5 Topics: Counseling; Humans; Lutetium; Male; Radioisotopes	2023

Trials

6 trial(s) available for lutetium and psma-617

Article	Year
[ The Lancet. Oncology, 2018, Volume: 19, Issue:6 Topics: Aged; Dipeptides; Disease Progression; Health Status; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Time Factors; Treatment Outcome; Victoria	2018
Results of a Prospective Phase 2 Pilot Trial of Clinical genitourinary cancer, 2019, Volume: 17, Issue:1 Topics: Aged; Aged, 80 and over; Dipeptides; Disease Progression; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Image Processing, Computer-Assisted; Lutetium; Male; Middle Aged; Pilot Projects; Positron-Emission Tomography; Prognosis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Rate	2019
Dosimetry of Molecules (Basel, Switzerland), 2019, Feb-11, Volume: 24, Issue:3 Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Marrow; Dipeptides; Glutamic Acid; Half-Life; Heterocyclic Compounds, 1-Ring; Humans; Infusions, Intravenous; Kidney; Lutetium; Male; Mannitol; Middle Aged; Parotid Gland; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radioisotopes; Radiopharmaceuticals; Tablets	2019
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. The New England journal of medicine, 2021, 09-16, Volume: 385, Issue:12 Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Middle Aged; Positron-Emission Tomography; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Analysis	2021
Circulating androgen receptor gene amplification and resistance to British journal of cancer, 2021, Volume: 125, Issue:9 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Dipeptides; Drug Resistance, Neoplasm; Gene Amplification; Heterocyclic Compounds, 1-Ring; Humans; Logistic Models; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Receptors, Androgen; Survival Analysis	2021
[ Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:11 Topics: Dipeptides; Docetaxel; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Survival Analysis; Treatment Outcome	2023

Other Studies

49 other study(ies) available for lutetium and psma-617

Article	Year
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:6 Topics: Animals; Antigens, Surface; Cell Line, Tumor; Chelating Agents; Chromatography, High Pressure Liquid; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Peptides; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Radiotherapy; Reproducibility of Results; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution	2015
SNMMI 2015 Image of the Year. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8 Topics: Antigens, Surface; Awards and Prizes; Baltimore; Dipeptides; Gallium; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; History, 21st Century; Humans; Lutetium; Male; Neoplasm Metastasis; Nuclear Medicine; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Medical	2015
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617. Clinical nuclear medicine, 2016, Volume: 41, Issue:7 Topics: Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome	2016
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients. Nuclear medicine and biology, 2016, Volume: 43, Issue:5 Topics: Animals; Cell Line, Tumor; Dipeptides; Drug Stability; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dosage; Rats; Rats, Wistar; Tissue Distribution; Translational Research, Biomedical	2016
Prospects of medium specific activity (177) Lu in targeted therapy of prostate cancer using (177) Lu-labeled PSMA inhibitor. Journal of labelled compounds & radiopharmaceuticals, 2016, Volume: 59, Issue:9 Topics: Aged; Antigens, Surface; Dipeptides; Drug Stability; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Quality Control; Radiochemistry; Radioisotopes	2016
The impact of repeated cycles of radioligand therapy using [ European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:9 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Hormones; Humans; Kidney; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Time Factors; Treatment Failure	2017
Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [ European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:9 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Survival Analysis; Treatment Outcome	2017
Aktuelle Urologie, 2017, Volume: 48, Issue:5 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies	2017
Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjugate chemistry, 2018, 09-19, Volume: 29, Issue:9 Topics: Animals; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Radiopharmaceuticals; Xenograft Model Antitumor Assays; Yttrium Radioisotopes	2018
Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Clinical nuclear medicine, 2019, Volume: 44, Issue:6 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage; Retrospective Studies; Single Photon Emission Computed Tomography Computed Tomography; Whole Body Imaging	2019
Concentration-dependent effects of dutasteride on prostate-specific membrane antigen (PSMA) expression and uptake of The Prostate, 2019, Volume: 79, Issue:12 Topics: 5-alpha Reductase Inhibitors; Antigens, Surface; Cell Line, Tumor; Dipeptides; Dose-Response Relationship, Drug; Dutasteride; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Receptors, Androgen; Up-Regulation	2019
Therapeutic efficacy, prognostic variables and clinical outcome of The British journal of radiology, 2019, Volume: 92, Issue:1104 Topics: Aged; Aged, 80 and over; Antigens, Surface; Dipeptides; Fluorodeoxyglucose F18; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Positron Emission Tomography Computed Tomography; Prognosis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome	2019
Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 ( The Journal of urology, 2020, Volume: 203, Issue:5 Topics: Dipeptides; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Theranostic Nanomedicine	2020
Prognostic biomarkers in men with metastatic castration-resistant prostate cancer receiving [177Lu]-PSMA-617. European journal of nuclear medicine and molecular imaging, 2020, Volume: 47, Issue:10 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Tomography, X-Ray Computed; Treatment Outcome	2020
A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy (PRRT): 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods. Journal of visualized experiments : JoVE, 2020, 04-24, Issue:158 Topics: Adult; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Imaging, Three-Dimensional; Lutetium; Male; Middle Aged; Neoplasms; Prostate-Specific Antigen; Radioisotopes; Radiometry; Receptors, Peptide; Single Photon Emission Computed Tomography Computed Tomography	2020
Prediction of response and survival after standardized treatment with 7400 MBq European journal of nuclear medicine and molecular imaging, 2021, Volume: 48, Issue:5 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome	2021
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA. European urology, 2021, Volume: 79, Issue:3 Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia	2021
PSMA-targeted therapy in prostate cancer. Clinical advances in hematology & oncology : H&O, 2021, Volume: 19, Issue:2 Topics: Adenocarcinoma; Antibodies, Bispecific; Antibodies, Neoplasm; Antigens, Surface; Biomarkers, Tumor; Clinical Trials as Topic; Dipeptides; Docetaxel; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Immunotherapy, Adoptive; Lutetium; Male; Molecular Targeted Therapy; Nanoparticles; Neoplasm Proteins; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Randomized Controlled Trials as Topic	2021
Identification, Characterization, and Suppression of Side Products Formed during the Synthesis of [ Journal of medicinal chemistry, 2021, 04-22, Volume: 64, Issue:8 Topics: Amino Acid Motifs; Cell Line; Chromatography, High Pressure Liquid; Cyclization; Density Functional Theory; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Magnetic Resonance Spectroscopy; Prostate-Specific Antigen; Radioisotopes; Radiopharmaceuticals; Spectrometry, Mass, Electrospray Ionization; Thermodynamics	2021
Intra-therapeutic dosimetry of [ European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:2 Topics: Hormones; Humans; Lutetium; Male; Organs at Risk; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Radiation Dosage; Radiopharmaceuticals; Single Photon Emission Computed Tomography Computed Tomography; Treatment Outcome	2022
Re: Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. European urology, 2021, Volume: 80, Issue:4 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes	2021
177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study). European journal of nuclear medicine and molecular imaging, 2022, Volume: 49, Issue:3 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Registries; Retrospective Studies; Treatment Outcome	2022
Evaluation of Molecular pharmaceutics, 2021, 12-06, Volume: 18, Issue:12 Topics: Animals; Chelating Agents; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Scandium; Tissue Distribution	2021
Should Lutetium-prostate specific membrane antigen radioligand therapy for metastatic prostate cancer be used earlier in men with lymph node only metastatic prostate cancer? Investigative and clinical urology, 2021, Volume: 62, Issue:6 Topics: Antigens, Surface; Antineoplastic Agents; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Analysis; Time-to-Treatment; Treatment Outcome; Tumor Burden	2021
Treatment outcome and identification of factors influencing overall survival after Lu-177-PSMA-617 radioligand therapy in metastatic prostate cancer. Nuklearmedizin. Nuclear medicine, 2022, Volume: 61, Issue:1 Topics: Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome	2022
In vitro and in vivo response of PSMA-617 radiolabeled with CA and NCA lutetium-177. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2022, Volume: 180 Topics: Animals; Cell Line, Tumor; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Mice; Mice, SCID; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Tissue Distribution; Xenograft Model Antitumor Assays	2022
Lutetium-177-PSMA-617 for Prostate Cancer. The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes	2021
Lutetium-177-PSMA-617 for Prostate Cancer. The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes	2021
Lutetium-177-PSMA-617 for Prostate Cancer. The New England journal of medicine, 2021, Dec-23, Volume: 385, Issue:26 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes	2021
Lutetium-177-PSMA-617 for Prostate Cancer. Reply. The New England journal of medicine, 2021, 12-23, Volume: 385, Issue:26 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes	2021
Lutetium-177-PSMA-617: A Vision of the Future. Cancer biology & therapy, 2022, 12-31, Volume: 23, Issue:1 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome	2022
Periodontal Disease Association with Large-Artery Atherosclerotic Stroke. Journal of neurological disorders & stroke, 2021, Volume: 8, Issue:1 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Matched-Pair Analysis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Urea	2021
Delayed Nephrotoxicity After 225Ac-PSMA-617 Radioligand Therapy. Clinical nuclear medicine, 2022, Jun-01, Volume: 47, Issue:6 Topics: Actinium; Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2022
Prostate Cancer Treatment: Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022, Volume: 63, Issue:6 Topics: Clinical Trials, Phase III as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; United States	2022
Pre- and intratherapeutic predictors of overall survival in patients with advanced metastasized castration-resistant prostate cancer receiving Lu-177-PSMA-617 radioligand therapy. BMC urology, 2022, Jul-04, Volume: 22, Issue:1 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies	2022
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. European urology, 2023, Volume: 84, Issue:1 Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Taxoids; Treatment Outcome	2023
Systemic Therapy Update on Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 11-01, Volume: 40, Issue:31 Topics: Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2022
Systemic Therapy Update on JCO oncology practice, 2023, Volume: 19, Issue:3 Topics: Dipeptides; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant	2023
Clinical Implementation of Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:3 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Longitudinal Studies; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; United States	2023
Extended therapy with [ European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:6 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm, Residual; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Treatment Outcome	2023
Increased PSMA Expression in 177 Lu-PSMA-617 Scan in Metastatic Castrate-Resistant Prostate Cancer Patient Treated With PSMA Radioligand Therapy and Enzalutamide : A Potential Game-Changer. Clinical nuclear medicine, 2023, May-01, Volume: 48, Issue:5 Topics: Androgen Antagonists; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
New Horizons in Radioligand Therapy: 161Tb-PSMA-617 in Advanced mCRPC. Clinical nuclear medicine, 2023, May-01, Volume: 48, Issue:5 Topics: Aged, 80 and over; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Terbium; Treatment Outcome	2023
Synthesis of tritium-labeled Lu-PSMA-617: Alternative tool for biological evaluation of radiometal-based pharmaceuticals. Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2023, Volume: 197 Topics: Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Pharmaceutical Preparations; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Tritium	2023
SNMMI Consensus Statement on Patient Selection and Appropriate Use of Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023, Volume: 64, Issue:9 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes	2023
Re: Timothée Olivier, Kerrington Powell, Vinay Prasad. Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial. Eur Urol. 2023;84:4-6. European urology, 2023, Volume: 84, Issue:4 Topics: Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Treatment Outcome	2023
Urinary excretion kinetics of [ European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:12 Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals	2023
Long-term survival outcomes of salvage [ European journal of nuclear medicine and molecular imaging, 2023, Volume: 50, Issue:12 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome	2023
Excellent Response to Full-Dose 177 Lu-PSMA-617 RLT in Metastatic Castration-Resistant Prostate Cancer With Transplant Kidney : A Step Ahead. Clinical nuclear medicine, 2023, Oct-01, Volume: 48, Issue:10 Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome	2023
Treatment of Multiple Bone Metastases of Castration-Resistant Prostate Cancer With 225 Ac-PSMA-617. Clinical nuclear medicine, 2023, Dec-01, Volume: 48, Issue:12 Topics: Bone Neoplasms; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Treatment Outcome	2023